Background. Thrombolytic therapy is an effective treatment modality for acute ischaemic stroke within 3 hours of symptom onset. Its safety and efficacy have not been studied in patients with chronic kidney disease (CKD), who are known to have abnormalities in coagulation and platelet function. Methods. We studied all patients who consecutively received intravenous thrombolytic therapy for acute stroke Results. Mean ± SD age was 66.4 ± 16.9 years with 39 (52.7%) men and 46 (62.2%) Caucasian. Twenty patients (27.0%) had eGFR <60 and were older, with a higher prevalence of diabetes and coronary artery disease than patients with eGFR ≥60. Presenting stroke severity, blood pressure and time to alteplase were similar in the two groups. Symptomatic ICH occurred in two patients with eGFR ≥60. Asymptomatic and symptomatic ICH considered together showed no difference in these event rates (20% in eGFR <60 vs 11.1% in eGFR ≥60, P = 0.321). There was no difference in poor functional status (70.0% in eGFR <60 vs 57.4% in eGFR ≥60, P = 0.324) or inhospital death outcomes (10.0% in eGFR <60 vs 7.4% in eGFR ≥60, P = 0.717). Multivariate logistic regression analysis revealed no association between eGFR <60 and in-hospital outcomes, while increasing age was associated with poor functional status [odds ratio 1.03 (1.00-1.06, P = 0.047)]. Conclusions. In our limited sample size study, presence of eGFR <60 in patients receiving thrombolytic therapy for acute stroke was not found to be associated with increased ICH, poor functional outcome or death. These findings suggest that use of thrombolytics in acute stroke is appropriate in patients with renal dysfunction.
the direct vasodilatory effects of venom. We also suspect that we overestimate AKI in Group A. Large numbers of people with <50 stings likely never seek medical attention.
Physicians in Vietnam have been alerted to the risks of rhabdomyolysis and AKI after hornet attacks. In district hospitals, they now initiate treatment with intravenous fluids on presentation and are vigilant for the development of AKI. Personal observations at CRH indicate that fewer patients are now presenting with AKI. Our colleagues at Oxford have developed an antivenom antibody and enzyme-linked immunoassay to measure serum venom levels. We hope to use this to correlate venom levels with number of stings and risks for specific clinical complications.
Methods
The case series consists of 65 patients admitted to CRH (Ho Chi Minh City, Vietnam) following multiple wasp stings typically in the spring and summer months. Upon admission, the patient's history was obtained including time, location and description of the insects, and initial symptoms. Each patient was examined for the number, location and characteristics of the stings. The patients were followed closely with particular attention to their urine output, kidney function and other pertinent laboratory tests. Haemodialysis was instituted at the discretion of the treating physician.
The insects involved in the attacks were brought by the patients' families who collected the insects at night by lighting fires which attract and stun the insects. Specimens were sent to the Hope Entomological Collections, University Museum of Oxford, for identification.
The case histories of 65 patients treated at CRH in the period from 1989 to 2000 were evaluated retrospectively. For the purposes of data analysis, the patients were subdivided based on the time of presentation (within 3 days and after 3days from being stung) to CRH and on the number of stings sustained (<50 stings and ≥50 or more stings), as represented in Results. Mean ± SD age was 66.4 ± 16.9 years with 39 (52.7%) men and 46 (62.2%) Caucasian. Twenty patients (27.0%) had eGFR <60 and were older, with a higher prevalence of diabetes and coronary artery disease than patients with eGFR ≥60. Presenting stroke severity, blood pressure and time to alteplase were similar in the two groups. Symptomatic ICH occurred in two patients with eGFR ≥60. Asymptomatic and symptomatic ICH considered together showed no difference in these event rates (20% in eGFR <60 vs 11.1% in eGFR ≥60, P = 0.321). There was no difference in poor functional status (70.0% in eGFR <60 vs 57.4% in eGFR ≥60, P = 0.324) or inhospital death outcomes (10.0% in eGFR <60 vs 7.4% in eGFR ≥60, P = 0.717). Multivariate logistic regression analysis revealed no association between eGFR <60 and in-hospital outcomes, while increasing age was associated with poor functional status [odds ratio 1.03 (1.00-1.06,
Introduction
Chronic kidney disease (CKD) is associated with an increased risk for stroke [1] . This phenomenon was initially observed in end-stage renal disease patients with a 4-10-fold greater stroke risk as compared to the general population [2, 3] . The increased risk for stroke persists in CKD patients not on dialysis by 1.5-3 times [4, 5] . Thrombolytic therapy with intravenous tissue plasminogen activator (tPA) is an effective treatment of acute ischaemic stroke in patients presenting within 3 hours of symptom onset [6] . Major clinical trials have demonstrated improved neurological outcomes with thrombolytic therapy but with an increased risk for intracranial haemorrhage (ICH) as a potential serious complication [7] [8] [9] . No distinction to the presence of CKD was made in these clinical trials, and so, it is not known whether CKD patients can achieve equally good functional outcomes or worse bleeding complications as compared to patients without CKD.
Patients with CKD are known to have abnormalities in coagulation and platelet function that favour thrombosis in the untreated state and then augment bleeding risks in the setting of antiplatelet drugs and anticoagulants [10, 11] . Prior studies have demonstrated increased levels of thrombin generation, circulating thrombin-antithrombin complex and plasminogen activator inhibitor in patients with CKD [12] . Platelet dysfunction in CKD has been attributed to intrinsic and extrinsic factors [13] . Factors intrinsic to platelets include impaired membrane glycoprotein function, abnormal release of adenosine phosphate and serotonin after platelet stimulation, depressed thromboxane A 2 generation and altered cytoskeletal assembly following platelet activation. Extrinsic factors include the action of uremic toxins, increased nitric oxide synthesis and abnormalities in von Willebrand factor leading to impairment in platelet-endothelium interaction. In aggregate, these platelet and plasma abnormalities have been shown to contribute to impaired platelet aggregation. Thus, patients with CKD are at risk for thrombotic and bleeding events at the same time [14] .
The systemic atherosclerotic vascular disease process seen with reduced renal function may partly explain its association with stroke [15] . Cardiovascular risk factors including hypertension, insulin resistance, endothelial dysfunction and inflammation are highly prevalent in CKD [16] . Small-vessel cerebrovascular disease has been described in CKD patients [17] [18] [19] . It can be hypothesized that chronic microvascular damage to the cerebral blood vessels in CKD may predispose these vessels to further injury and rupture in the setting of an acute stroke after thrombolytic therapy. A haemorrhagic transformation of the infarct may thus be possible from reperfusion injury when the tPA recanalizes the occluded blood vessels. Abnormalities in platelet function and platelet-endothelial interactions in CKD may increase bleeding risk in these patients. These disturbances may offset the beneficial effect of tPA in CKD as suggested by a clinical trial of tPA use in acute myocardial infarction [20] . No study has reported the safety and efficacy of thrombolytic therapy in patients with CKD presenting with acute ischaemic stroke.
We performed this retrospective observational study on all patients presenting with acute ischaemic stroke to our hospital who received intravenous tPA as part of the stroke treatment protocol. We studied these patients for the presence of renal dysfunction on admission and evaluated its impact on inpatient clinical outcomes of ICH, functional improvement and inpatient mortality.
Materials and methods

Study population
Thrombolytic therapy for acute stroke was started in William Beaumont Hospital Royal Oak MI, a tertiary care teaching hospital, in October 2005. We identified all patients who received tPA for acute ischaemic stroke from October 2005 to January 2009 (n = 78) through electronic medical records. We excluded four patients who received intra-arterial tPA due to a different time frame for tPA administration (beyond 3 hours), and invasiveness of the neurointerventional procedure. Thus, all consecutive patients receiving intravenous tPA for acute ischaemic stroke with time of documented symptom onset <180 minutes before initiating tPA therapy were included in the final analysis (n = 74). This included five patients who received intravenous tPA at nearby health facilities and were transferred to our hospital for close monitoring and continuation of care.
Patients presenting with neurological symptoms and measurable deficits who were clinically diagnosed with acute stroke were evaluated in the emergency centre by the attending physician. The thrombolytic pathway was activated if patients presented within 180 minutes of stroke onset. This involved urgent evaluation by a stroke nurse practitioner for eligibility for tPA therapy (Table 1 ). The nurse practitioner performed detailed history and physical exam including collection of data on onset of symptoms, evaluation of stroke risk factors (by patient/family recall and previous medical records), review of patient medications and contraindications to tPA therapy (Table 1 ) and calculation of the National Institute of Health (NIH) stroke scale at presentation. The contraindications to tPA in our stroke protocol are similar to those in the National Institute of Neurological Disorders (NINDS) trial [7] . Of note, CKD or dialysis therapy was not a contraindication to use of thrombolytics and patients on warfarin anticoagulation were candidates for tPA if international normalized ratio was ≤1.7. Stat laboratory tests were performed including complete blood count, basic metabolic panel, prothrombin and activated prothrombin time. A stat non-contrast head computed tomography (CT) was obtained and interpreted by a neuroradiologist to evaluate for ICH that would constitute an absolute contraindication to tPA therapy.
After a decision on eligibility for tPA was reached jointly by the emergency centre attending and consultant neurologist on call and consent was obtained from the patient or family, intravenous alteplase (0.9 mg/ kg; maximum dose 90 mg) was administered stat. No dose adjustment of alteplase was made for renal insufficiency as it undergoes hepatic clearance [21] . The patient was then admitted to the medical intensive care unit for continuous monitoring, and all antiplatelet and anticoagulants were held for the first 24 hours post-tPA. A repeat non-contrast CT was routinely performed 24-36 hours after the initial CT and or at the time of any neurological worsening to determine ICH or oedema. Magnetic resonance imaging/angiography was performed at the discretion of the neurologist. As per the stroke protocol, all patients were to undergo carotid artery Doppler study and 2D echocardiogram. The patient was evaluated by physical therapist on Day 2-3 to determine the appropriate disposition based on the functional status and followed till discharge.
Data collection
Approval of the study was obtained from the Human Investigation Committee at William Beaumont Hospital, Royal Oak MI. Medical charts were abstracted using a standardized form by an investigator (B.R.). Data was collected on patient demographics, time of onset of stroke symptoms, home medications and stroke risk factors from the stroke nurse practitioner's note. History of hypertension, diabetes, hyperlipidaemia, prior stroke (or transient ischaemic attack), atrial fibrillation, smoking (current or past) and coronary artery disease (prior heart revascularization procedures) were per patient recall or past medical history of the patient as documented in the chart. A computerized laboratory information system was accessed to review laboratory and imaging studies performed at admission. Serum creatinine was obtained from the admission basic metabolic panel and evaluated in William Beaumont Hospital Reference Laboratory by a colorimetric method using a Jaffe rate method. . Admission clinical parameters including NIH stroke scale, blood pressure and dose of alteplase were collected. Significant carotid stenosis was present if there was >70% occlusion on carotid Doppler study. Congestive heart failure was present if the ejection fraction on echocardiogram was <40%.
Definition of in-hospital outcomes
The outcomes of interest were development of ICH, functional status at discharge [(as per modified Rankin scale (mRS)] and in-hospital mortality. The neuroradiology reports of the follow-up CT scans (routine or symptom prompted) obtained within 48 hours of tPA were reviewed by two investigators (B.R. and V.A.). ICH was classified as symptomatic if there was concurrent neurological deterioration as documented in the note of the ordering physician. Petechial haemorrhages were defined as presence of separate haemorrhagic spots within the infarct area and were asymptomatic. Parenchymal haemorrhage was defined as a confluent, hyperdense haematoma. The mRS score [22] was evaluated from the physical therapy notes closest to discharge by an investigator (B.R.) trained by the stroke nurse practitioner. After the mRS score was assessed on all patients, mRS was dichotomized in two ways: favourable (mRS 0-1) or unfavourable (mRS 2-6) neurological outcomes [7] , and functional independence (mRS 0-2) or dependence or death (mRS 3-6) [8] . An mRS score of 6 indicates patient death. In-hospital mortality and the reasons for death were also recorded during chart review.
Statistical analysis
Baseline characteristics, admission parameters and outcome measures were expressed as mean ± standard deviation or counts with proportions as appropriate. NIH stroke scale and length of hospital stay were expressed as median with interquartile range due to skewed distribution and studied for difference by Kruskall-Wallis test. Univariate comparisons were made between patients with or without renal dysfunction with the Student's t-test or chi-square test as appropriate.
Step-down multivariable logistic regression analysis was used with unfavourable outcome (mRS 2-6), functional dependence or death (mRS 3-6), all ICH events and death as the dependent variables in four models. The independent variables in all models were age in years, presence of diabetes mellitus, and presence of eGFR <60. These variables were chosen from prior studies and due to the small number of outcomes in our study. The least significant variable was dropped at each step until only those variables with a P-value < 0.05 remained in the final model. The odds ratio and associated 95% confidence interval were estimated to determine the association between those variables and the in-hospital outcomes. All hypothesis testing was two-tailed. A P-value < 0.05 was considered statistically significant. Statistical analysis was performed with SPSS, Inc., Version 14.0, Chicago, IL, USA.
Results
The 74 patients in our study had a mean age of 66. Table 2 shows baseline characteristics of the study sample. Patients with eGFR <60 were significantly older (74.4 ± 12.9 years) than patients with eGFR ≥60 (63.4 ± 17.3years; P = 0.012). Patients with eGFR <60 had higher prevalence of diabetes mellitus (50% vs 22.2% in patients with eGFR ≥60, P = 0.020), coronary artery disease (55% vs 25.9% in patients with eGFR ≥60, P = 0.019) and atrial fibrillation (45% vs 20.4% in patients with eGFR ≥60, P = 0.034). Patients with eGFR <60 had a greater prevalence of hypertension, hyperlipidaemia, congestive heart failure and use of statins that approached significance. Clinical and laboratory parameters of the patients prior to tPA therapy are also presented in Table 2 . Median NIH stroke scale scores, mean time from symptom onset to treatment and mean blood pressures were similar in both groups. Mean serum glucose was higher in patients with eGFR <60 (166.8 ± 48.6 mg/dl) than patients with eGFR ≥60 (135.6 ± 63.0 mg/dl, P = 0.049), while platelet count was lower, but not significantly different, in patients with eGFR <60.
In-hospital outcomes are shown in Table 3 . Parenchymal haemorrhage developed in three patients with eGFR ≥60 (symptomatic in two patients) and in one patient with eGFR <60 (asymptomatic). Another patient with eGFR ≥60 developed subarachnoid haemorrhage (asymptomatic). None of these complications necessitated neurosurgical intervention. Considering asymptomatic and symptomatic ICH together, there was no significant difference in the incidence of ICH between patients with and without renal dysfunction (20 vs 11.1%, respectively, P = 0.321).
The distribution of mRS scores on all patients at discharge is presented in Figure 1 with stratification by presence of eGFR <60. We observed that worse neurological outcomes when defined as unfavourable outcome (mRS 2-6) or dependency or death (mRS 3-6) were higher among patients with eGFR <60 (85 and 70%, respectively) but not significantly different from that in patients with eGFR ≥60 (68.5 and 57.4%, respectively) ( Table 3 ). Median length of hospital stay was similar. In-hospital mortality was slightly higher in patients with eGFR <60 as compared to patients with eGFR ≥60 but not significantly different (10 vs 7.4%, respectively, P = 0.717) ( Table 3) . None of the deaths were due to ICH, while cerebral oedema (n = 3), sepsis (n = 2) and cardiac arrest (n = 1) were the causes of death. Multivariate logistic regression analyses revealed that presence of eGFR <60 did not predict ICH (all types) (P = 0.373), unfavourable neurological outcome (P = 0.254), dependency or death (P = 0.671) or in-patient death (P = 0.652) ( Table 4) . Patient age (for every 1 year increase) was found to predict dependency or death outcomes (mRS 3-6) with an odds ratio 1.03 (1.00-1.06) that had a significant P-value (P = 0.047) with moderate accuracy (C-statistic=0.643).
Discussion
To our knowledge, this is the first report characterizing inhospital outcomes of thrombolytic therapy for acute stroke in association with the presence of renal dysfunction. The main finding of our study was that incidence of symptomatic ICH complications after tPA therapy in patients with eGFR <60 was not greater compared to patients with eGFR ≥60. Incidence of all ICH considered together was slightly higher but not significantly different among both groups, and was not affected by presence of eGFR <60 in the regression model. We found that poor neurological status and inhospital death were not more common in the presence of eGFR <60. We observed age to be a mild, yet significant, predictor of functional dependency or death (mRS 3-6) after adjusting for the presence of eGFR <60 and diabetes.
Increasingly, tPA is being used for treatment of acute ischaemic stroke with great safety. [23] Symptomatic ICH is a serious complication of tPA, and thus identification of its predictors may help improve selection of patients for this therapy. Few studies have assessed outcomes of stroke in patients with CKD [24] [25] [26] or dialysis, [27, 28] but no details on tPA use were reported. Given the increased risk for stroke with CKD and growing number of patients with CKD [29] , it is important to study stroke outcomes after thrombolytic therapy in the presence of renal dysfunction. Several features regarding our study deserve mention. There were 20 patients (27%) with eGFR <60 ml/min/1.73 m 2 that approximates the CKD prevalence (29.5%) found in patients with ischaemic stroke [24] . Our patients were elderly as in most clinical studies of stroke. As expected, patients with an eGFR <60 had a higher rate of comorbidities including diabetes, and cardiovascular disease. The neurological deficit at presentation (as evaluated by NIH stroke scale score), blood pressure, time to administration of thrombolytic and tPA dose were similar between patients with eGFR <60 and eGFR ≥60.
We initially hypothesized that patients with renal dysfunction may have increased bleeding complications after tPA due to microvascular damage and platelet dysfunction. This may explain the high risk for incident haemorrhagic stroke seen in CKD [30] and dialysis patients [31, 32] . Post hoc analyses of clinical trials and observational studies have reported elderly age (>70 years), diabetes, infarct size on presentation, presenting NIH stroke scale score >20, hyperglycaemia (serum glucose >200 mg/dl) and elevated blood pressure to be significant predictors of symptomatic ICH after tPA [33, 34] . Despite greater age and prevalence of diabetes, symptomatic ICH was not more frequent in patients with eGFR <60 in our study. Another report found presence of renal insufficiency to be similar in patients without ICH (2.1%) and with ICH (0%) [35] . This may suggest factors other than vessel wall integrity or platelet dysfunction such as matrix metalloproteinase-9 and fibronectin that are involved in extracellular matrix remodelling and endothelial damage to be important in predicting haemorrhagic complications [36] . We recognize that our sample size and event rates were small, and we did not have standard neuroradiology reports of presenting infarct size that would represent the volume of ischaemic tissue at risk for haemorrhagic complication. Our study adds to the current literature by demonstrating that eGFR <60 is not a risk factor for combined asymptomatic and symptomatic ICH and suggests that presence of eGFR <60 should not preclude use of tPA in acute ischaemic stroke due to concerns of ICH.
Numerous clinical factors including time to thrombolytic therapy, hyperglycaemia, restoration of cerebral blood flow, baseline NIH stroke scale score, high blood pressure and history of diabetes are associated with lack of neurological improvement after tPA therapy [37, 38] . We expected patients with eGFR <60 to have worse functional outcomes after stroke due to cardiovascular comorbidities ACE/ARB = angiotensin-converting enzyme inhibitor/angiotensin receptor blockers, eGFR = estimated glomerular filtration rate, NIH = National Institute of Health, TIA = transient ischaemic attack, tPA = tissue plasminogen activator, iv = intravenous. All data are expressed as mean ± SD except for NIH stroke scale score (median and interquartile range). There was missing data on NIH scores (n = 5), dose of alteplase (n = 8), haemoglobin A1c (n = 11), carotid stenosis (n = 5) and lipid panel (n = 4).
and probable impaired thrombus dissolution and recanalization [39] as in a prospective study [24] . The distribution of mRS scores in our study suggested relatively worse outcomes (mRS ≥2) in patients with eGFR <60 though this failed to achieve significance. A similar pattern existed for in-hospital mortality. Our results are similar to another study that reported similar creatinine levels in patients with or without functional impairment 24 hours after tPA [40] . However, these findings need to be interpreted with caution as assessment of mRS is subjective and may be influenced by investigator bias. We observed age to be a significant predictor of dependency or death (mRS 3-6) after tPA use, likely due to cerebral amyloid angiopathy and delicate microvasculature. However, this finding has not been consistently observed with some reports showing worse [41, 42] or similar [43, 44] functional outcomes in patients ≥80 years with acute stroke, and thus, elderly age is not a contraindication for thrombolytic use. Our rate of in-hospital deaths after tPA (8.2%) approximates that found in other registries (10%) [45, 46] , but no deaths occurred from ICH. Our findings, though favourable and preliminary, have important implications for neurologists, emergency centre physicians and nephrologists who may be consulted for an opinion on risk of tPA in CKD patients presenting with acute stroke. Investigators planning clinical trials of thrombolytics or neuroprotective agents may need to consider outcome stratification by CKD. Diagnostic and therapeutic interventions have traditionally been underutilized in the management of acute coronary syndrome, a close resemblance to acute stroke, in the presence of CKD [47] . Causes for this pattern may include perceived high complication rates in CKD, unclear therapeutic efficacy in CKD due to exclusion from clinical trials or therapeutic nihilism. Whether these reasons influence stroke outcome in CKD is not known, but it certainly is plausible. Our study demonstrates that presence of CKD should not deter physicians from using tPA in acute ischaemic stroke if patients are carefully selected by NINDS criteria and closely monitored for bleeding complications, but the possibility of type 1 error from small size and event rate should be recognized. Furthermore, it may be important to encourage use of thrombolytic therapy in patients with CKD and stroke if long-term functional status and mortality are proven to be worse in this high-risk population. A recent clinical trial demonstrated benefit of thrombolytic use up to 4.5 hours after stroke onset [48] , however its implication in CKD patients is not known. Future prospective studies or stroke registries can give a better understanding of management patterns and outcomes in CKD patients with stroke.
Our study has numerous strengths and limitations. All consecutive patients who received tPA for acute stroke at our hospital were studied. All patients received protocoldriven post-thrombolytic intensive care monitoring, repeat imaging and physical therapy thus minimizing differences in care to a large extent. Our study was retrospective and from a single centre thus limiting sample size and ability * P = 0.0471. The odds ratio for age is for each increase of 1 year in age. DM = diabetes mellitus, CKD = chronic kidney disease, mRS = modified Rankin score. to adjust for other covariates. The decision to evaluate patient eligibility for tPA was at the discretion of the emergency centre physician and the neurologist thus leading to possible bias in selecting patients with less severe deficits or those felt to be at low risk for complications. This process may have excluded more patients with renal impairment though we do not have this information. We do not have data on deviation of patient care from stroke protocol that may have affected our findings. Details on baseline or prior disability were not available for adjustment of neurological improvement. Renal dysfunction was diagnosed based on presenting creatinine that may not represent a steady state (i.e. acute kidney injury and/or chronic kidney disease) potentially leading to misclassification with MDRD estimation equation. Urine protein studies were not routinely performed that may have identified more patients with renal dysfunction. Long-term outcomes could not be assessed due to lack of such data.
In conclusion, the present study suggests that patients with eGFR <60 presenting with acute ischaemic stroke and who receive protocol-driven thrombolytic therapy by NINDS criteria have in-hospital outcomes of symptomatic ICH, poor functional status and death similar to patients without renal dysfunction. Our findings support that, until data is obtained from randomized controlled trials or large databases, appropriately selected patients with renal dysfunction should not be excluded from administration of intravenous tPA therapy for acute ischaemic stroke.
